Skip to main content

Share story

Products

Gemini 3.1 Pro released by Google DeepMind

Gemini 3.1 Pro released by Google DeepMind Image: Primary
Google DeepMind released Gemini 3.1 Pro, an upgraded version of the core intelligence in the Gemini 3 series. The model is being shipped across consumer and developer products. The release follows a major update last week to Gemini 3 Deep Think for challenges across science, research and engineering. Gemini 3.1 Pro is a smarter baseline for complex problem solving. On the ARC-AGI-2 benchmark for solving new logic patterns, the model achieved a verified score of 77.1 percent. This is more than double the reasoning performance of 3 Pro. Access is available in preview for developers through the Gemini API in Google AI Studio, Gemini CLI, Google Antigravity and Android Studio. Enterprises can use the model in Vertex AI and Gemini Enterprise. Consumers have access via the Gemini app and NotebookLM. Google said it is releasing the model in preview to validate updates before general availability soon. Users with Google AI Pro and Ultra plans receive higher limits in the Gemini app. The model is also available on NotebookLM for those plan users.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from ai and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.